Skip to main content

Advertisement

Table 2 Pharmacokinetic parameters (non-compartmental analysis) of [9-14C]-oleic acid and/or its metabolites in plasma and blood of Göttingen minipigs after a single oral dose of [9-14C]-Oleic to untreated minipigs (group A) and minipigs that were pre-treated with 2 tablets of 500 mg formoline L112 (group B)

From: A single oral dose of a polyglucosamine influences the bioavailability of [9-14C]-Oleic acid in adult female Göttingen minipigs

Group A B %a A B %a
  Plasma   Blood  
Pharmacokinetic parameters
Tmax (h) 4 ± 3 16 ± 9* - 4 ± 3 14 ± 11 -
Cmax (μg/g) 14.1 ± 3.6 3.3 ± 1.2** 23.4 8.5 ± 2.2 2.1 ± 0.8** 24.7
AUC(0-12h) (h* μg/g) 65.6 ± 6.0 21.6 ± 14.0** 32.9 40.0 ± 4.8 13.3 ± 9.1** 33.3
AUC(0-24h) (h* μg/g) 98.4 ± 17.2 49.9 ± 20.8** 50.7 61.7 ± 13.1 29.8 ± 12.9** 48.3
AUC(0-48h) (h* μg/g) 136 ± 28 91.0 ± 23.2* 66.9 88.3 ± 19.0 56.9 ± 13.1* 64.4
AUC(0-60h) (h* μg/g) 148 ± 31 105 ± 25* 70.9 97.2 ± 20.6 67.3 ± 13.8* 69.2
AUC(0-72h) (h* μg/g) 157 ± 32 116 ± 26 73.9 105 ± 22 76.4 ± 14.2* 72.8
AUCall(0-144h) (h* μg/g) 190 ± 38 158 ± 32 83.2 139 ± 25 118 ± 16 84.9
Vz (g/kg) 7008 ± 2962 5629 ± 1946 - 8860 ± 1848 9515 ± 1647 -
Cl (g/h/kg) 40.7 ± 5.5 49.8 ± 8.3 - 48.4 ± 7.9 47.6 ± 7.3 -
MRTlast (h) 35.9 ± 1.8 50.2 ± 5.1** - 43.6 ± 3.1 58.4 ± 5.7** -
  1. aPercentage of radioactivity remaining in plasma or blood following pre-treatment with formoline L112 compared to the untreated control group
  2. * P ≤ 0.05, ** P ≤ 0.01